Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 8/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 8/20 | 0.47 |
| ▸ | FYN | P06241 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30129746 | 0.88 | HSD17B1 (0.47) | HSD17B1HSD17B2FYNCYP3A4CYP2C9 | |
| SCHEMBL3594129 | 0.75 | CYP3A4 (0.47) | FYNCYP3A4CALM1 | |
| SCHEMBL29461940 | 0.72 | HSD17B1 (0.44) | HSD17B1HSD17B2FYNCYP3A4CYP2C9 | |
| SCHEMBL12763310 | 0.72 | KIT (0.66) | FYNDYRK1ADYRK1B | |
| SCHEMBL3014425 | 0.68 | BIRC5 (0.66) | HSD17B1HSD17B2CYP3A4CYP2C9MAP4K4 | |
| SCHEMBL3013447 | 0.68 | ESR2 (0.72) | HSD17B1HSD17B2CYP3A4CYP2C9DYRK1A | |
| SCHEMBL69369 | 0.67 | HSD17B1 (0.88) | HSD17B1HSD17B2CYP3A4CYP2C9MEN1 | |
| SCHEMBL29551999 | 0.67 | HSD17B1 (0.88) | HSD17B1HSD17B2CYP3A4CYP2C9MEN1 | |
| SCHEMBL30129623 | 0.67 | HSD17B1 (0.57) | HSD17B1HSD17B2FYNMAP4K4 | |
| SCHEMBL23407768 | 0.66 | SNCA (0.71) | CYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230027684-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230008867-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008867-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | HSD17B1 2388/4885HSD17B2 2816/4885FYN 1660/4885 |
| US-20230027684-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | HSD17B1 2342/4885HSD17B2 2758/4885FYN 1417/4885 |
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | HSD17B1 2342/4885HSD17B2 2758/4885FYN 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.